NYKD — Nykode Therapeutics ASA Share News
0.000.00%
- NOK870.25m
- NOK450.97m
Brief: Nykode Announces Expanded Clinical Development Plan For Its Lead Cancer Vaccine VB10.16
Brief: Nykode Therapeutics And Richter-Helm Biologics Announce Strategic Manufacturing Partnership
Brief: Nykode Therapeutics Enters Clinical Collaboration With MSD
Brief: Nykode Therapeutics Q3 Oper Loss Widens To $19.9 Million
Brief: Nykode Therapeutics Announces Positive Results From Phase 1/2 Open Label, Dose Escalation Trial Of SARS-CoV-2 Vaccine Candidate
Brief: Nykode Therapeutics Q2 Net Loss Widens To $8.7 Million
Brief: Vaccibody Enters Into Worldwide License Agreement With Adaptive Biotechnologies
Brief: Vaccibody: Promising Preclinical Data With COVID-19 Vaccine Candidate In Mice